Medytox to sell off 2.2 mn shares of Daewoong's American partner Evolus

The S.Korean pharmaceutical company will move down as the third-largest shareholder for the US company

Medytox headquarters in Seoul
Medytox headquarters in Seoul
Jae-Young Han 1
Feb 08, 2023 (Gmt+09:00) jyhan@hankyung.com
Bio & Pharma

Medytox Inc. said in a regulatory filing on Wednesday that it is selling off approximately 2.19 million shares of Evolus, Daewoong Pharmaceutical's US partner, for 23.2 billion won ($18.5 million).

Medytox has been the largest shareholder of Evolus, but once the disposal is completed, it will move down as the third-largest shareholder with 5 million shares (9.1% stake).

Evolus is a local partner that sells Daewoong Pharmaceutical's botulinum toxin drug Nabota in the United States.

Medytox reached an agreement with Evolus in early 2021, at the end of the US International Trade Commission lawsuit against Daewoong Pharmaceutical surrounding the sale of Nabota.

At the time, Evolus issued its common stock and provided it to Medytox at face value while providing the settlement money.

"The sale of our stake is intended to improve management efficiency," said a Medytox official.

Write to Jae-Young Han at jyhan@hankyung.com
#Medytox #Daewoong Pharmaceutical #Evolus #Nabota #botulinum toxin

Medytox to build plant for finished toxin products in Dubai

Medytox to build plant for finished toxin products in Dubai

Marwan Abdulaziz Janahi, CEO of Dubai Science Park(left) and Jung Hyunho, CEO of Medytox South Korea's biopharmaceutical company Medytox Inc. will build a plant for finished products containing botulinum toxin in the United Arab Emirates (UAE) in what will be the first such facility abroad cons

Medytox-Hugel dispute over botox strain intensifies with ITC probe

Medytox-Hugel dispute over botox strain intensifies with ITC probe

Hugel is Korea’s largest botox maker A legal dispute over a botox strain between South Korean pharmaceutical company Medytox Inc. and its crosstown rival Hugel Inc. has intensified with the International Trade Commission (ITC) officially launching an investigation into the case.The US tra

Medytox files complaint with ITC against Hugel over botox strain

Medytox files complaint with ITC against Hugel over botox strain

Korean botox maker Medytox South Korean pharmaceutical company Medytox Inc. has filed a complaint with the International Trade Commission (ITC) against Hugel Inc., alleging that the crosstown rival has poached its botulinum toxin strain.Hugel, Korea’s largest manufacturer of botulinum tox

Medytox’s US business outlook dim as contract with AbbVie ends

Medytox’s US business outlook dim as contract with AbbVie ends

Korean botox maker Medytox South Korea’s pharmaceutical company Medytox Inc. has ended a botulinum toxin-related technology transfer contract with AbbVie, clouding its business outlook in the US.AbbVie has returned the rights concerning a botulinum toxin, more commonly known as botox, can